13D Filing: Versant Venture Capital IV, L.P. and Crispr Therapeutics AG (CRSP)

Page 2 of 18

Page 2 of 18 – SEC Filing

 

CUSIP No.   71723F103

13D

 

 

 

1.

Name of Reporting Persons
Versant Venture Capital IV, L.P.

 

 

2.

Check the Appropriate Box if a Member of a Group (See Instructions)

 

 

(a)

 o

 

 

(b)

 x(1)

 

 

3.

SEC Use Only

 

 

4.

Source of Funds (See Instructions)
WC

 

 

5.

Check if Disclosure of Legal Proceedings Is Required Pursuant to Item 2(d) or 2(e)     o

 

 

6.

Citizenship or Place of Organization
Delaware, United States

 

Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With

7.

Sole Voting Power
2,736,032 shares of common stock (2)

 

8.

Shared Voting Power
0

 

9.

Sole Dispositive Power
2,736,032 shares of common stock (2)

 

10.

Shared Dispositive Power
0

 

 

11.

Aggregate Amount Beneficially Owned by Each Reporting Person
2,736,032 shares of common stock (2)

 

 

12.

Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions)   o

 

 

13.

Percent of Class Represented by Amount in Row 11
6.74% (3)

 

 

14.

Type of Reporting Person (See Instructions)
PN

 


(1) This Schedule 13D is filed by Versant Venture Capital IV, L.P. (VVC IV), Versant Side Fund IV, L.P. (VSF IV), Versant Venture Capital V, L.P. (VVC V), Versant Affiliates Fund V, L.P. (VAF V), Versant Ophthalmic Affiliates Fund I, L.P. (VOA) and Versant Venture Capital V (Canada) LP (VVC CAN).  Versant Ventures IV, LLC (VV IV) is the sole general partner of VVC IV and VSF IV. Brian G. Atwood (Atwood), Samuel D. Colella (Colella), Ross A. Jaffe (Jaffe), William J. Link (Link), Rebecca B. Robertson (Robertson), Bradley Bolzon, Ph.D (Bolzon)., Charles M. Warden (Warden), Kirk G. Nielsen (Nielsen), Thomas Woiwode (Woiwode) and Robin L. Praeger (Praeger) are managing directors of VV IV. Versant Ventures V, LLC (VV V) is the sole general partner of VVC V, VAF V and VOA. Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V.  Versant Ventures V GP-GP (Canada), Inc. (VV V CAN GP) is the sole general partner of Versant Ventures V (Canada), L.P. (VV V CAN, and, together with VVC IV, VSF IV, VV IV, VVC V, VV V, VAF V, VOA, VVC CAN, and VV V CAN GP, the Reporting Persons).  VV V CAN is the sole general partner of VVC CAN.  Colella, Link, Bolzon, Praeger, Nielsen and Woiwode are managing directors of VV V CAN GP.  The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13D.

(2) The shares are held by VVC IV. VV IV is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. Atwood, Colella, Jaffe, Link, Robertson, Bolzon, Warden, Nielsen, Woiwode and Praeger are managing directors of VV IV and share voting and dispositive power over the shares held by VVC IV; however, they each disclaim beneficial ownership of the shares held by VVC IV except to the extent of their pecuniary interests therein.

(3) This calculation is based upon 40,591,669 Common Shares outstanding as of August 7, 2017, as reported in the Issuers 10-Q filed with the Securities and Exchange Commission (the SEC) on August 10, 2017.

 

2


Follow Crispr Therapeutics Ag (NASDAQ:CRSP)

Page 2 of 18